25 May 2016 - The EMA has published an EPAR for eftrenonacog alfa (Alprolix).

The European Commission approved Alprolix on 12 May 2016 for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004142/human_med_001973.jsp&mid=WC0b01ac058001d124